Egypt Kidney Cancer Therapeutics Market Report 2023 to 2030

Egypt Kidney Cancer Therapeutics Market Analysis

$ 3999

The Egypt Kidney Cancer Therapeutics Market was valued at $17.61 Mn in 2023 and is predicted to grow at a CAGR of 6.36% from 2023 to 2030, to $27.12 Mn by 2030. The key drivers of this industry include the rising incidence of kidney cancer, advancements in treatment options, and the growing aging population. The industry is primarily dominated by players such as AstraZeneca, Pfizer, Novartis, Bayer, Roche, Bristol Myers Squibb, Merck, Abbott, Amgen, and Takeda Pharmaceutical.

ID: IN10EGPH350 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Aashwi Mehta

Buy Now

Egypt Kidney Cancer Therapeutics Market Executive Summary

The Egypt Kidney Cancer Therapeutics Market was valued at $17.61 Mn in 2023 and is predicted to grow at a CAGR of 6.36% from 2023 to 2030, to $27.12 Mn by 2030.

Kidney cancer refers to the abnormal proliferation of cells in the kidney tissue. A tumor is a mass that develops from these cells over time. Hematuria, a lump or mass in the kidney area, fatigue, anemia, loss of appetite, and flank pain are some of the symptoms. Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. Other types include transitional cell carcinoma, Wilms tumor, and renal sarcoma. Several risk factors contributing to kidney cancer can be further divided into modifiable and non-modifiable factors. Smoking and Obesity are the two major modifiable factors responsible for kidney disease, whereas age and gender are the non-modifiable ones.

The estimated number of new cases is 2,259 with a cumulative risk of about 0.26%. Most of the kidney cases reported are at an advanced stage. The total number of deaths is predicted to be 990. The market is driven by significant factors like the rising incidence of kidney cancer, advancements in treatment options, and the growing aging population. However, stringent regulatory processes, higher costs, and side effects related to treatment restrict the growth and potential of the market.

Prominent players in this field include AstraZeneca, Pfizer, Novartis, Bayer, Roche, Bristol Myers Squibb, Merck, Abbott, Amgen, and Takeda Pharmaceutical.

Market Dynamics

Market Growth Drivers

Rising incidence of Kidney cancer: There is an estimated 2,259 new cases of kidney cancer in Egypt. As new and better treatments are sought to meet this urgent medical need, Egypt's renal cancer therapeutics market is expected to rise significantly due to the high incidence and mortality, which drives demand for advanced renal cancer therapeutics.

Advancements in treatment options: The introduction of targeted treatments, and immunotherapies, among other recent developments, is greatly expanding the range of available treatment options and improving patient outcomes. Because of these developments, there is a greater need for advanced therapies, which propels the market, providing pharmaceutical companies with a great chance of meeting the increasing need for indicated therapies.

Growing Aging Population: Egypt is undergoing a demographic shift, with the number of people over 60 predicted to more than double from 8.4 million (8% of the overall population) to 22 million (14%), between 2020 and 2050. Given that an aging population raises the incidence of renal cancer and consequently increases demand for related treatments, this demographic shift is a major market driver for Egypt's renal cancer therapeutics market.

Market Restraints

Stringent Regulatory Process: Before any drug product may be sold or delivered in Egypt, it must be approved by the Egyptian Drug Authority. For new market entrants, navigating the legal environment and achieving the strict standards might be challenging.

High Cost of Treatment: Cancer imposes a significant economic burden on patients, their families, and healthcare providers in Egypt. The high out-of-pocket (OOP) costs for specialized treatment and therapy, impact household expenditure, posing a restraint on the renal cancer therapeutics market.

Side Effects of Treatment: Side effects from kidney cancer treatments represent a major market restraint. These negative effects may limit the use of specific therapies and decrease patient compliance, which may affect the overall efficacy of those therapies. Renal cancer therapeutic market growth and innovation are hampered by patients' and healthcare providers' reluctance to embrace novel treatments due to the possibility of severe adverse effects.

Regulatory Landscape and Reimbursement Scenario

The Ministry of Health (MOH)'s Egyptian Drug Authority (EDA) is responsible for overseeing the nation's pharmaceutical regulations. Within the EDA, numerous entities collaborate to guarantee that all pharmaceuticals are properly regulated to ensure efficient public access while upholding compliance. The goal of Egypt's Universal Health Insurance (UHI) program is to offer all residents complete healthcare coverage. The UHI is a government initiative that guarantees the availability and affordability of vital health services, including cancer treatments.

Competitive Landscape

Key Players

Here are some of the major key players in the Egypt Kidney Cancer Therapeutic Market

AstraZeneca
Pfizer
Novartis
Bayer
Roche
Bristol Myers Squibb
Merck
Abbott
Amgen
Takeda Pharmaceutical

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Egypt Kidney Cancer Therapeutics Market Segmentation

By Cancer Type

Wilms tumor
Clear Cell Renal Carcinoma
Transitional Cell Carcinoma
Others

By Treatment

Targeted Therapy
Immunotherapy
Radiation Therapy
Surgeries

By End Users

Hospitals
Specialty Centres
Ambulatory Surgical Centres

By Distribution Channel

Hospital-based pharmacies
Retail pharmacies
Online pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.